A dual-lock strategy for tumor-specific pyroptosis activation plus gas synergism

released during activation further consumes GSH and amplifies the ROS storm, which ultimately triggers the caspase-3/GSDME-mediated pyroptosis pathway in tumor cells, remodels the immunosuppressive tumor microenvironment, and exerts potent therapeutic efficacy in tumor-bearing mouse models. This study not only exploits a new molecular platform for multimodal tumor theranostics, but also offers a safe and potent innovative strategy to precisely trigger tumor cell pyroptosis for high-efficiency cancer immunotherapy.